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Abstract
As part of the single technology appraisal process, the National Institute for Health and Care Excellence invited Merck to 
submit evidence for the clinical and cost effectiveness of cladribine tablets (cladribine) for the treatment of relapsing-remitting 
multiple sclerosis (RRMS). Rapidly evolving severe (RES) and sub-optimally treated (SOT) RRMS were specified by the 
National Institute for Health and Care Excellence as subgroups of interest. The Liverpool Reviews and Implementation Group 
at the University of Liverpool was the Evidence Review Group. This article summarises the Evidence Review Group’s review 
of the company’s evidence submission for cladribine and the Appraisal Committee’s final decision. The final scope issued 
by the National Institute for Health and Care Excellence listed the following disease-modifying treatments as comparators: 
alemtuzumab, daclizumab, fingolimod and natalizumab. At the time of the company submission, a licence was anticipated for 
low-dose cladribine. The main clinical evidence (the CLARITY trial) in the company submission focused on the efficacy of 
low-dose cladribine vs. placebo. The CLARITY trial showed a statistically significant reduction in relapse rate for cladribine 
in the RES-RRMS subgroup (n = 50) but not in the SOT-RRMS subgroup (n = 19). Cladribine showed a numerical, but not 
a statistically significant, advantage in delaying disability progression at 6 months in the RES-RRMS subgroup. Disability 
progression benefits could not be estimated for those in the SOT-RRMS subgroup because of few events. The Evidence 
Review Group’s main concern regarding the clinical evidence was the small sample size of the subgroups. To compare the 
effectiveness of cladribine to other disease-modifying treatments, the company conducted network meta-analyses, which 
showed cladribine and its comparators to be equally effective. The Evidence Review Group considered the results of the 
disease-modifying treatments to be unreliable because few trials were in the network. The company’s cost-effectiveness 
evidence showed cladribine to be cheaper and more effective than other disease-modifying treatments in the RES-RRMS 
arm and the SOT-RRMS arm. The results were most sensitive to treatment effect on disability progression at 6 months. 
The Evidence Review Group was concerned that there was insufficient evidence to conclude that cladribine was superior to 
placebo in delaying disability progression. The Evidence Review Group amended the company’s economic model to allow 
alternative estimates for the treatment effect of cladribine and its comparators on relapse rate and disability progression at 
6 months. The Evidence Review Group made other changes to the company model. After implementing all the amendments, 
cladribine remained cost effective in the RES-RRMS and SOT-RRMS subgroups. The Appraisal Committee recognised the 
uncertainty in the available data but concluded that cladribine could be considered a cost-effective use of National Health 
Service resources.
Extended author information available on the last page of the article
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Key Points 
The European Medicines Agency withdrew the market-
ing authorisation for daclizumab over safety concerns 
in 2018 and the National Institute for Health and Care 
Excellence (NICE) has subsequently withdrawn its 
guidance on daclizumab for treating relapsing-remitting 
multiple sclerosis (RRMS).
Before NICE withdrew its guidance on daclizumab, 
Merck submitted clinical and cost-effectiveness evidence 
to NICE to support the use of cladribine in patients with 
rapidly evolving severe RRMS and sub-optimally treated 
RRMS in the UK. The comparators were alemtuzumab, 
daclizumab, fingolimod and natalizumab.
An independent Evidence Review Group critiqued the 
submission and concluded that the available evidence 
has not sufficiently demonstrated cladribine to be clini-
cally more effective or cost effective compared to its 
comparators.
The NICE Appraisal Committee considered that while 
there was considerable uncertainty around the available 
evidence, cladribine was likely to represent a cost-effec-
tive use of National Health Service resources.
1 Introduction
The National Institute for Health and Care Excellence 
(NICE) is an independent organisation whose remit is to 
provide national guidance to the National Health Service 
(NHS) in England and Wales on a range of clinical and 
public health issues, including the appraisal of new health 
technologies. The NICE single technology appraisal (STA) 
process is designed for the appraisal of a single health tech-
nology for a single indication shortly before or after a UK 
marketing authorisation is granted for the technology. NICE 
develops a document (the final scope) that sets out the ques-
tions potential appraisals should address. The scope specifies 
the population and subgroups of interest, potential compara-
tors to technology, health outcome measures and other spe-
cific considerations.
As part of the STA process, the company submits evi-
dence on the clinical and cost effectiveness of the technol-
ogy, including a de novo economic model. The evidence 
necessary to address the scope of the appraisal is expected 
to originate from a single company or any of its associated 
companies [1]. An external independent organisation, known 
as the Evidence Review Group (ERG) provides a critique 
of the company’s submission (the ERG report). The NICE 
Appraisal Committee (AC) considers the company’s submis-
sion (CS), the ERG report, and testimonies from clinical 
experts and stakeholders to determine whether the tech-
nology represents clinical and cost-effective use of NHS 
resources. All stakeholders and the public have an oppor-
tunity to comment on the preliminary guidance issued by 
NICE in the form of an appraisal consultation document, 
after which the AC meets again to produce the final guidance 
(final appraisal determination). The final guidance consti-
tutes a legal obligation for NHS providers in England and 
Wales to provide a technology that is approved within its 
licensed indication [2].
This article presents a summary of the ERG report by 
the Liverpool Reviews and Implementation Group at the 
University of Liverpool for the STA of cladribine tablets 
(cladribine) for the management of patients with multiple 
sclerosis (MS). Merck was the sponsoring company for this 
STA. Full details of all documents relevant to this appraisal 
(including the appraisal scope, ERG report, company and 
consultee submissions, NICE guidance and comments on 
each of these) can be found on the NICE website [3].
2  Background and Decision Problem
2.1  Background
Multiple sclerosis is the most common debilitating neuro-
logical disease in young adults [4]. The disease is character-
ised by autoimmune-mediated inflammation, demyelination 
and the development of plaque lesions in the central nervous 
system resulting in progressive disability [5]. About 85% of 
patients diagnosed with MS initially present with a relaps-
ing-remitting (RRMS) disease pattern. For these patients, 
episodes of acute disease exacerbation (relapse) interrupt 
periods of partial or complete recovery (remission) [5].
The Expanded Disability Status Scale (EDSS) is used 
to quantify the disability of patients living with MS. The 
time it takes to reach an EDSS score of 6, defined as a dis-
ability level at which patients require assistance to walk, 
ranges from 15 to 32 years from onset of the disease. Many 
factors, such as age at onset of the disease and relapse rate, 
affect disease progression for patients with RRMS [6]. The 
disease course for patients with RRMS is more aggressive 
in those who are categorised as having high disease activity 
RRMS (HDA-RRMS) [7]. This group of patients includes 
those with rapidly evolving severe (RES) RRMS despite 
adequate treatment and others with RRMS who are sub-
optimally treated (SOT) [8]. Some patients with RRMS can 
progress to develop secondary progressive multiple sclero-
sis (SPMS) within 20 years following disease onset, where 
progressive neurodegeneration and permanent disability 
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persist irrespective of exacerbation episodes. Highly active 
relapsing MS is another term used in clinical practice to 
describe a broad population that comprises patients with 
HDA-RRMS and the relapsing form of SPMS. A noteworthy 
point is that patients with MS are grouped into these popula-
tions based on a combination of their clinical symptoms and 
the number of plaque lesions in the brain following detection 
with magnetic resonance imaging (MRI), and the number of 
brain lesions only has a moderate correlation with clinical 
symptoms [9].
Currently, there is no cure for MS. Consequently, the 
main goals of clinicians managing patients with RRMS 
are to reduce the frequency and severity of relapses and to 
delay disability progression by prescribing disease-modi-
fying therapies (DMTs). NICE recommended natalizumab 
[10] in 2007 and fingolimod [11] in 2012 as therapies for 
patients with RES-RRMS and SOT-RRMS, respectively. In 
2014, [12] NICE recommended alemtuzumab for treating 
patients with active RRMS, which includes patients with 
RES-RRMS and SOT-RRMS. In 2017, daclizumab was rec-
ommended for use in patients with RES-RRMS and patients 
with previously treated for active RRMS (that is, including 
patients with SOT-RRMS) in whom alemtuzumab is either 
unsuitable or contraindicated [13]. The European Medicines 
Agency (EMA) withdrew marketing authorisation for dacli-
zumab in 2018 following reports of serious inflammatory 
brain disorders, including three fatalities worldwide [14]. 
The EMA was also concerned that treatment with dacli-
zumab may be linked to immune reactions in other organs, 
and that the drug should not be commenced in new patients 
[14]. NICE has since withdrawn its guidance on daclizumab 
for treating RRMS.
2.2  Decision Problem
The intervention considered in this appraisal was cladribine. 
The mechanism by which cladribine exerts its therapeutic 
effects in MS is not fully clear but its effect on B and T 
lymphocytes interrupts immune events that exacerbate MS. 
A unique feature of cladribine is discontinuous immuno-
suppression: a phenomenon whereby periods of lymphocyte 
depletion during treatment are followed by a gradual repopu-
lation back to normal levels resulting in durable efficacy well 
beyond the period of treatment [15]. The implication is that 
cladribine (an oral medication) can be given in two cycles 
that are 12 months apart with no treatment in between [15]. 
The company stated that the infrequent dosing and the oral 
administration route of cladribine coupled with the added 
benefit of not requiring monitoring above the standard care 
represents an innovation [16].
Cladribine is licensed in Europe for use in adults with 
highly active relapsing MS. Previously, the company 
received two negative opinions in response to its marketing 
authorisation applications to the EMA for the treatment 
of patients with RRMS in 2009 and for the treatment of 
patients with HDA-RRMS in 2010. On these occasions, the 
EMA was concerned about the safety profile of treatment 
with cladribine. The appraisal discussed in this paper was 
prompted by the company’s latest application for marketing 
authorisation in June 2016 for which the company provided 
new efficacy and safety evidence. The company expected an 
authorisation only for adults with HDA-RRMS; however, 
the EMA issued a positive opinion for adults with highly 
active relapsing MS [17] on 22 June, 2017, 4 days before 
the company made this submission to NICE.
The population described in the final scope issued by 
NICE is adults with RRMS. The scope also sets out differ-
ent comparators for (1) patients who have not had previous 
treatment, (2) patients who have received previous treat-
ment, (3) patients with RES-RRMS and (4) patients with 
highly active RRMS despite previous treatment, which the 
company termed as SOT-RRMS. The company provided 
clinical effectiveness evidence for patients with RRMS, 
HDA-RRMS, RES-RRMS and SOT-RRMS. Only the RES-
RRMS and SOT-RRMS subgroups were considered in the 
company’s economic analyses (Table 1). No evidence was 
provided in the CS for other subgroups specified in the final 
scope, especially for patients with RRMS who are planning 
pregnancy.
3  Independent Evidence Review Group 
Report
The evidence provided by the company comprised an initial 
submission, a cost-effectiveness model (which is commer-
cial in confidence) and the company’s response to the ERG’s 
clarification requests. The ERG report [18] is a summary 
and a critical review of the evidence for the clinical and cost 
effectiveness of the technology provided by the company. 
The aims of the report were to:
• assess whether the evidence submitted by the company 
conforms to the methodological guidelines issued by 
NICE;
• assess whether the company’s interpretation and analysis 
of the evidence are appropriate;
• indicate the presence of other sources of evidence or 
alternative interpretations of the evidence that could help 
inform the development of NICE guidance.
In addition to providing this detailed critique, the ERG 
modified several key company model assumptions and 
parameters to explore the robustness of the company’s cost-
effectiveness results.
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3.1  Clinical Evidence
3.1.1  Direct Evidence
At the time of writing their CS, there was no head-to-head 
trial comparing the effectiveness of cladribine with treat-
ment with any of the other relevant comparators. There-
fore, the main evidence that the company provided for the 
effectiveness of cladribine was from a placebo-controlled 
study, the CLARITY trial [19, 20]. The CLARITY trial was 
a randomised, double-blinded, multicentre phase III trial 
designed to investigate the efficacy of cladribine in patients 
with RRMS. A total of 1326 patients were randomised 1:1:1 
to receive either low-dose cladribine (3.5-mg/kg cumulative 
dose over 2 years; n = 433), high-dose cladribine (5.25-mg/
kg cumulative dose over 2 years; n = 456) or placebo over 
2 years (n = 437). The company focused on data from the 
low-dose cladribine (referred to as cladribine from here on 
unless otherwise specified) tablet arm, for which an EMA 
license was anticipated. Data from the cladribine arm and 
the placebo arm formed the intention-to-treat (ITT) popu-
lation in the CS. In terms of subgroups, the HDA-RRMS 
subgroup was pre-planned in the CLARITY trial, [21] but 
the RES-RRMS (n = 50) and SOT-RRMS (n = 19) sub-
groups were defined post-hoc [22] to address the subgroups 
described in the NICE decision problem.
In the cladribine arm, 91.9% (398/433) of participants 
completed the study and 91.2% (395/433) completed treat-
ment. Eighty-seven per cent (380/437) of participants in the 
placebo arm completed the study, with 86.3% completing 
treatment. Results showed that treatment with cladribine was 
statistically significantly better than placebo for all outcomes 
addressed, when assessed using data from the ITT popula-
tion and those from the HDA-RRMS subgroup (see Table 2).
Results for the RES-RRMS subgroup were mixed, with 
treatment with cladribine being statistically significantly bet-
ter than placebo in terms of qualifying annualised relapse 
rate (ARR) and time to first relapse; however, treatment 
with cladribine did not statistically significantly delay the 
time to 3-month confirmed disability progression (CDP) or 
time to 6-month CDP. For all but one outcome, there was no 
evidence that cladribine was statistically significantly better 
than placebo for patients in the SOT-RRMS subgroup. The 
exception was the post-hoc composite efficacy outcome ‘no 
evidence of disease activity’ (NEDA-3), which was defined 
as no relapses, no 3-month confirmed EDSS progression, no 
new or enhancing T1 gadolinium-enhancing (Gd+) lesions, 
and no new or enlarging T2 lesions [22, 23]. In terms of this 
NEDA-3, treatment with cladribine was statistically signifi-
cantly better than placebo in the ITT population and in all 
subgroup populations.
The adverse events (AEs) reported in the CS were 
derived from participants in the CLARITY trial who were 
randomised to receive cladribine at a dose of 3.5 mg/kg 
(n = 430) or placebo (n = 435) and who received at least 
one study treatment. No AE data were provided for the 
RES-RRMS and SOT-RRMS subgroups. Overall, the pro-
portion of participants reporting treatment-emergent AEs 
in the cladribine arm and placebo arm was similar (80.7% 
vs. 73.3%). The company reported that more patients in the 
cladribine arm experienced serious treatment-emergent AEs 
than in the placebo arm (8.4% vs. 6.4%).
The company included data from the CLARITY-EXT 
trial [24] in the CS. The CLARITY-EXT trial was a 2-year 
extension of the CLARITY trial, which explored whether 
the treatment effect observed during the CLARITY trial per-
sisted in the absence of additional treatment. Participants 
who had received cladribine in the CLARITY trial were 
allowed to receive cladribine in the CLARITY-EXT trial. 
The rank preserving structural failure time model [25] and 
the iterative parameter estimation algorithm were used to 
estimate the effect of having these patients who had ini-
tially received placebo but then went on to receive cladribine 
in the CLARITY-EXT trial. Results from the company’s 
Table 1  Summary of populations and comparators in the final scope issued by the National Institute for Health and Care Excellence and in the 
company submission for the economic analysis. Source: Company submission, Table 62
RES rapidly evolving severe, RRMS relapsing-remitting multiple sclerosis, SOT sub-optimally treated
Population in the final scope Comparators 
in the final 
scope
Population considered in the economic analysis Comparators in the 
economic analysis
Patients with RES-RRMS Alemtuzumab
Daclizumab
Natalizumab




Patients with RES-RRMS in whom alemtuzumab is contraindicated or are 
otherwise unable to receive alemtuzumab (RES-RRMSb)
Natalizumab
Daclizumab
Patients with highly active 









Patients with SOT-RRMS in whom alemtuzumab is contraindicated or are 
otherwise unable to receive alemtuzumab (SOT-RRMSb)
Fingolimod
Daclizumab
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analyses suggested that the effect of cladribine was constant 
over the 4 years for which data were available. However, the 
company noted that the effectiveness of cladribine beyond 
4 years remained uncertain.
3.1.2  Indirect Evidence
The company performed network meta-analyses (NMAs), 
where data were available, for several efficacy, safety and 
health-related quality of life (HRQoL) outcomes in the 
populations of interest (ITT, HDA-RRMS, RES-RRMS 
and SOT-RRMS). Data sources used within the NMAs were 
obtained from the published clinical literature, and from 
unpublished study reports for the CLARITY and PRISMS 
[26] trials. Forty-four studies contributed to the network. 
Some of the included studies had participants with a pro-
gressive disease, and did not report results separately for the 
RRMS-only population.
The results of the NMAs showed that the comparative 
data for cladribine vs. the relevant comparators within all 
of the subgroups were limited (Table 3). The limitation was 
pronounced for the SOT-RRMS subgroup as there were 
no comparative data for time to 3-month CDP and time 
to 6-month CDP. Treatment with cladribine was statisti-
cally significantly better than placebo at reducing ARR in 
the RES-RRMS subgroup. Cladribine also demonstrated 
a numerical advantage over placebo in delaying time to 
3-month CDP and 6-month CDP, but these benefits were 
not statistically significant. In the SOT-RRMS subgroup, 
treatment with cladribine only showed a numerical but not 
a statistically significant advantage compared with placebo.
When comparative data were available, the NMA results 
showed that treatment with cladribine was not statistically 
significantly better than any of the relevant comparators in 
terms of ARR, 3-month CDP and 6-month CDP. There were 
outcomes for which cladribine was numerically superior and 
at other times, the comparators were numerically superior 
to cladribine.
The company urged that the NMA results (Tables 3, 4) 
should be interpreted with caution owing to the heterogene-
ity between the studies with respect to study phase, eligibil-
ity criteria, baseline EDSS, treatment history and the onset 
of disease symptoms. The company acknowledged that the 
lack of published data linking the control arm of studies 
evaluating alemtuzumab via a network made it challeng-
ing to compare alemtuzumab to other therapies listed in the 
final scope issued by NICE for the treatment of patients with 
RES-RRMS and SOT-RRMS. Comparative 6-month CDP 
efficacy results were key inputs for the economic model, 
but published data on this outcome were particularly lim-
ited. The company, therefore, conducted an additional meta-
regression analysis to attempt to generate a more robust 
comparison of 6-month CDP between cladribine and its 
Table 2  CLARITY trial primary and secondary efficacy outcomes
ARR annualised relapse rate, CI confidence interval, CDP confirmed disability progression, HAD-RRMS high disease activity relapsing-remit-
ting multiple sclerosis, HR hazard ratio, ITT intention-to-treat, K-M Kaplan–Meier, NEDA-3 no evidence of disease activity at 3 months
a HR estimate is rate ratio
Outcome Cladribine Placebo HR (95% CI) P value
ITT population n = 433 n = 437
 Qualifying ARR (95% CI)a 0.14 (0.12–0.17) 0.34 (0.30–0.38) 0.42 (0.33–0.53) < 0.001
 Time to first qualifying relapse K-M estimate, % (95% CI) 80.3 (76.1–83.8) 61.1 (56.2–65.6) 0.45 (0.34–0.58) < 0.0001
  Qualifying relapse-free participants at 48 weeks, n (%) 353 (81.5) 300 (68.6) – –
 Time to 3-month CDP K-M estimate, % (95% CI) 85.1 (81.3–88.2) 76.3 (71.9–80.2) 0.59 (0.43–0.81) 0.0011
  Participants with 3-month CDP at 48 weeks, n (%) 377 (87.1) 340 (77.8) – –
 Time to 6-month CDP K-M estimate, % (95% CI) 90.6 (87.4–93.1) 83.3 (79.3–86.6) 0.53 (0.36–0.78) 0.0014
  Participants with 6-month CDP at 48 weeks, n (%) 386 (89.1) 348 (79.6) – –
 Time to NEDA-3 status K-M estimate, % (95% CI) 40.1 (34.5–45.6) 12.6 (8.8–17.0) 2.21 (1.88–2.61) 0.0001
HDA-RRMS n = 140 n = 149
 Qualifying ARR (95% CI)a 0.16 (0.12–0.22) 0.46 (0.38–0.55) 0.35 (0.24–0.50) < 0.0001
 Time to first qualifying relapse K-M estimate, % (95% CI) 77.1 (68.8–83.5) 53.3 (44.7–61.2) 0.40 (0.26–0.61) < 0.0001
  Qualifying relapse-free participants at 48 weeks, n (%) 112 (80.0) 89 (59.7) – –
 Time to 3-month CDP K-M estimate, % (95% CI) 91.0 (84.7–94.8) 71.7 (63.4–78.5) 0.28 (0.15–0.54) 0.0001
  Participants with 3-month CDP at 48 weeks, n (%) 126 (90.0) 109 (73.2) – –
 Time to 6-month CDP K-M estimate, % (95% CI) 95.5 (90.2–97.9) 77.7 (69.8–83.8) 0.18 (0.08–0.44) 0.0001
  Participants with 6-month CDP at 48 weeks, n (%) 129 (92.1) 112 (75.2) – –
 Time to NEDA-3 status K-M estimate, % (95% CI) 43.7 (35.0–52.0) 6.9 (2.8–13.6) 2.86 (2.14–3.81) 0.0002
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comparators using guidance from a technical support docu-
ment [27] produced by the NICE decision support unit.
As all comparisons within the meta-regression were 
vs. placebo, the comparator interventions were compared 
in terms of the numerical results and overlap of credible 
intervals. Meta-regression results showed that treatment 
with cladribine was predicted to be more efficacious than 
alemtuzumab, but less efficacious than natalizumab and 
daclizumab for the RES-RRMS subgroup. Results also 
showed that treatment with cladribine was more efficacious 
than alemtuzumab and fingolimod, but less efficacious than 
daclizumab for the SOT-RRMS subgroup. However, none 
of the meta-regression results was statistically significant. 
The company concluded that the meta-regression predicted 
all comparators to be less effective for patients in the SOT-
RRMS subgroup than for those with RES-RRMS and that, 
owing to the significant overlap in the credible intervals 
across all comparisons, no therapy was statistically signifi-
cantly dominant.
3.2  Critique of the Clinical Evidence 
and Interpretation
3.2.1  Direct Evidence
The ERG considered that the CLARITY trial was of good 
quality and was well conducted. The company presented 
effectiveness evidence for three subgroups of participants, 
two of which were defined post-hoc. The ERG acknowl-
edged that the company’s post-hoc definition of subgroups 
was necessary to address the NICE decision problem, but 
noted that small subgroups reduced the statistical power 
of such analyses and the post-hoc definition of subgroups 
added to the uncertainty around the results. With only 19 
patients in the SOT-RRMS subgroup, it was always going 
to be unlikely that any results generated using the subgroup 
data would have the statistical power to detect a differ-
ence between treatments. Two post-hoc efficacy outcomes 
(NEDA-3, and 6-month CDP) were presented in the CS. 
These outcomes were chosen to demonstrate prolonged effi-
cacy in the reduction in disability progression in patients 
treated with cladribine compared with placebo. Clinical 
advice to the ERG was that NEDA-3 and CDP scores have 
not been validated as predictors of long-term outcome and 
that the result of these post-hoc analyses should, therefore, 
be interpreted with caution. The ERG noted that the result 
of ‘time to achieve NEDA-3 status’ in the SOT-RRMS sub-
group should be interpreted with caution as this was the only 
outcome for which a statistically significant advantage to 
cladribine over placebo was observed.
Table 3  Summary of the 
network meta-analysis results 
between cladribine and 
comparators for intention-
to-treat (ITT) population 
and post-hoc subgroups. 
Source: Company submission, 
Appendix D, adapted from 
Tables 11–13
A random-effects model was applied to the NMA for the ITT population and a fixed-effects model was 
applied to the NMA for the HDA-RRMS, RES-RRMS and SOT-RRMS subgroups
ARR annualised relapse rate, CDP confirmed disability progression, HDA high disease activity, NMA net-
work meta-analysis, RES rapidly evolving severe, RRMS relapsing-remitting multiple sclerosis, SOT sub-
optimally treated, ↑ indicates better efficacy for cladribine, ↑ indicates statistically significantly better effi-
cacy for cladribine, ↓ indicates lower efficacy for cladribine, ↔ indicates equivalent efficacy of cladribine 
and comparator, – indicates that NMA was not feasible, either owing to a lack of connections within the 
networks or a lack of studies
Cladribine vs. ARR 3-month CDP at 24 months 6-month CDP at 24 months
ITT HDA RES SOT ITT HDA RES SOT ITT HDA RES SOT
Placebo ↑ ↑ ↑ ↑ ↑ ↑ ↑ – ↑ ↑ ↑ –
Alemtuzumab ↓ ↔ ↓ – ↓ – – – ↓ ↑ ↓ –
Daclizumab ↔ – ↑ – ↔ – – – ↔ – – –
Fingolimod ↔ ↔ ↑ ↔ ↑ ↑ ↔ – ↑ – – –
Natalizumab ↓ ↓ ↓ – ↓ – ↓ – ↓ – ↓ –
Table 4  Network meta-analysis (NMA) for qualifying annualised 
relapse rate for cladribine vs. relevant comparators for the intention-
to-treat (ITT) population and the high disease activity relapsing-
remitting multiple sclerosis (HDA-RRMS) subgroup. Source: Com-
pany submission, Appendix D, Table 14
A random-effects model was applied to the NMA for the ITT popula-
tion and a fixed-effects model was applied to the NMA for the HDA-
RRMS subgroup
CrI credible interval, RES rapidly evolving severe, RR rate ratio
a The NMA was not feasible, either owing to a lack of connections 
within the networks or a lack of studies
Cladribine ITT HDA-RRMS
Median RR (95% CrI) Median RR (95% CrI)
Placebo 0.42 (0.32–0.54) 0.35 (0.24–0.51)
Alemtuzumab 1.31 (0.95–1.82) 0.99 (0.59–1.66)
Daclizumab 0.92 (0.67–1.26) a
Fingolimod 0.91 (0.68–1.23) 0.95 (0.58–1.54)
Natalizumab 1.24 (0.89–1.71) 1.14 (0.70–1.84)
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3.2.2  Indirect Evidence
The ERG considered that the company’s general approach 
to undertaking NMAs was appropriate. However, the com-
pany did not provide information about the number of par-
ticipants contributing to the NMAs of the key efficacy out-
comes for the post-hoc subgroups, except for 6-month CDP 
at 24 months in the RES-RRMS subgroup. Furthermore, the 
ERG was unable to extract the participant numbers, partici-
pant characteristics, and the definitions used in the trials for 
the RES-RRMS and SOT-RRMS subgroups from the pub-
lished literature of all of the trials. The ERG acknowledged 
that fitting random-effect models within small networks is 
difficult and agreed that the use of fixed-effect models may 
have been appropriate for the subgroups. However, as base-
line characteristics and heterogeneity measures within the 
post-hoc subgroups were not available, the ERG noted that it 
was difficult to judge whether important statistical inconsist-
ency or heterogeneity was present within the results for the 
subgroups; hence, it was difficult to interpret the numerical 
NMA results within the subgroups.
The company also performed a meta-regression. How-
ever, in light of the company’s stated objective, the ERG 
was not convinced that the results of the company’s meta-
regression provided more robust results than those of the 
NMAs. The ERG noted that the meta-regression approach 
outlined in the NICE Decision Support Unit document [27] 
is used to explore treatment-covariate interactions, such as 
an interaction between treatment effect and baseline risk, as 
a source of heterogeneity. The ERG was uncertain whether 
the methods in the Decision Support Unit document were 
valid for using baseline risk estimates to predict treatment 
effect for specific subgroups.
3.3  Cost‑Effectiveness Evidence
The company’s economic evaluation compared the cost 
effectiveness of cladribine with alemtuzumab, daclizumab, 
fingolimod and natalizumab (Table 1) in patients with RES-
RRMS and SOT-RRMS. Using Microsoft Excel, the com-
pany built a simplified version of other economic models 
that, since 2005, had been submitted to NICE as part of 
STAs of drugs for treating MS. Previously submitted mod-
els [10–13] had a 21-health-state structure: ten EDSS-based 
health states for patients with RRMS, another ten EDSS-
based health states for patients with SPMS and one state for 
all-cause mortality. The submitted company model for this 
appraisal, however, comprised 11 health states, having ten 
EDSS-based states and one additional state for death from 
all causes (Fig. 1). The company justified the use of the 
simpler model on the grounds that HRQoL is more reliably 
stratified by EDSS state alone, [28, 29] rather than by EDSS 
state and the clinical form of MS (RRMS and SPMS). The 
company noted that identifying and modelling the transi-
tion from the RRMS subtype into the SPMS subtype would 
have been challenging given that the use of SPMS-specific 
health states required data on SPMS-specific transition rates. 
The company considered the only available data on SPMS-
specific transition rates (the London Ontario Registry) to 
be too limited.
On model entry, individuals with RES-RRMS and SOT-
RRMS in the model were assigned to each of the EDSS 
health states based on the distribution of participants in the 
CLARITY trial at baseline. At the end of each 1-year cycle, 
there was a risk of moving to a higher EDSS state, moving to 
a lower EDSS state, remaining in the current EDSS state or 
dying. The risk of experiencing one or more acute relapses 
or discontinuing treatment was modelled as events within 
Fig. 1  Health-state structure of the company model showing the ten Expanded Disability Status Scale (EDSS)-based health states while taking 
disease-modifying drugs (DMDs) or not taking DMDs. SPMS secondary progressive multiple sclerosis. Source: Company submission, Fig. 12
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each EDSS-based health state. Individuals who discontinued 
DMTs were modelled to receive best supportive care.
Costs were calculated as a function of EDSS health 
state, number of relapses and time in each state. Included 
costs comprised drug cost (acquisition, administration and 
monitoring), hospital admission, outpatient care, relapse and 
informal care. Health-related quality of life for patients in 
EDSS 0–5 was obtained from the CLARITY trial. The EQ-
5D-3L questionnaires were administered on day 1, week 24, 
week 48, week 72, week 96 and at each relapse evaluation 
during the CLARITY trial. Data from completed question-
naires were converted to utility values using the UK social 
tariff. The company also carried out a systematic literature 
review to identify relevant HRQoL data. Following an 
assessment of available evidence, the company used data 
from published studies [30, 31] for EDSS 6–9. The company 
reports that its approach is in line with the approach taken 
in previously submitted company models [10–13, 32, 33].
The model had a lifetime time horizon (50 years) and 
NHS and personal and social services perspectives. All costs 
were expressed in UK pounds sterling for the 2015/2016 
price year. Health outcome was measured in quality-adjusted 
life-years (QALYs). The company presented results as incre-
mental cost-effectiveness ratios (ICERs) per QALY gained, 
using list prices for all drugs. A 3.5% annual discount rate 
was applied to costs and QALYs [2]. The company carried 
out a wide range of deterministic sensitivity analyses for the 
comparison of cladribine vs. treatment with other DMTs that 
were within the final scope issued by NICE for RES-RRMS 
and SOT-RRMS.
The company’s base-case deterministic ICERs per QALY 
gained showed that cladribine dominated all comparators, 
by being more clinically effective at a lower cost. Cladrib-
ine was particularly cost effective for patients with RES-
RRMS for whom alemtuzumab was either contraindicated 
or not tolerable. In this subgroup, cladribine delivered the 
largest QALY gain per patient (0.924) when compared with 
daclizumab, and generated the largest cost savings vs. natali-
zumab (£130,676). The results showed that the base-case 
analyses were most sensitive to variation in the effect of 
DMTs on 6-month CDP.
3.4  Critique of the Cost‑Effectiveness Evidence 
and Interpretation
The ERG considered the company’s model to be generally 
well structured and was satisfied with the company’s ration-
ale for using a simplified 11 health-state model rather than 
a 21 health-state model. The main issues with the company 
model were concerns with the treatment effectiveness esti-
mates for cladribine and its comparators, and the inclusion 
of costs and outcomes that were outside of the scope speci-
fied by NICE.
3.4.1  Treatment Effect Estimate for Cladribine
The company used the point estimates for ARR and 6-month 
CDP that were obtained from the CLARITY trial as efficacy 
data for cladribine. The point estimates suggested that clad-
ribine was superior to placebo for both efficacy outcomes 
for the RES-RRMS and SOT-RRMS subgroups. The ERG 
considered that the direct evidence presented by the com-
pany supports the conclusion that cladribine is superior to 
placebo but only for the RES-RRMS subgroup and only for 
qualifying ARR. When the ERG modelled its interpreta-
tion of the CLARITY trial data for the RES-RRMS sub-
group, treatment with alemtuzumab dominated cladribine, 
cladribine was less costly and generated fewer QALYs vs. 
natalizumab and daclizumab but at a cost per QALY lost 
that favoured the use of cladribine. Because evidence from 
the CLARITY trial suggests that treatment with cladribine 
is not statistically significantly better than placebo in terms 
of ARR or 6-month CDP for patients with SOT-RRMS, the 
ERG considered that there was no robust basis on which to 
construct an economic model for that subgroup.
The ERG expressed concerns about the robustness of the 
methods that were used to derive the comparative estimates 
on ARR (from the NMA) and 6-month CDP (from the meta-
regression). The company had modelled the effect of DMTs 
on progression between EDSS states by applying the hazard 
ratios for 6-month CDP from the meta-regression analysis 
to baseline transition probabilities. The ERG was concerned 
about the robustness of the meta-regression. However, even 
if the results from the company’s statistical analyses were 
robust for both the RES-RRMS and SOT-RRMS subgroups, 
the credible interval of the hazard ratio for all DMTs over-
lapped and the point estimates were similar.
The company modelled relapse rates as a function of 
time by multiplying the number of patients alive by ARR. 
Similar to the 6-month CDP results, the ARR results for 
each DMT (cladribine and it comparators) vs. placebo in the 
SOT-RRMS subgroup showed that the point estimates for 
the comparators were similar and resided within the credible 
intervals of every other DMT. The picture was slightly less 
clear for the RES-RRMS subgroup. The ARR point estimate 
for cladribine, alemtuzumab and daclizumab compared to 
placebo were further apart than those for the SOT-RRMS 
subgroup but still resided in each other’s credible intervals. 
The point estimate for natalizumab only resided in the alem-
tuzumab credible interval, but the credible interval for natal-
izumab nonetheless overlapped with those of other DMTs.
The ERG considers that, in situations where confidence/
credible intervals overlap and point estimates are similar, 
the appropriate approach is to assume equal efficacy for 
all treatment options. As such, the ERG assumed that the 
6-month CDP hazard ratios for all comparators were the 
same as those generated by the company’s meta-regression 
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for cladribine. The ERG also assumed that the ARR result 
in the RES-RRMS subgroup was the same for all DMTs 
other than natalizumab. These changes had no effect on the 
company’s base-case cost-effectiveness results as cladribine 
dominated all of the other comparators.
3.4.2  Treatment Effect over Time
The company analysed the CLARITY-EXT data in an 
attempt to provide robust evidence about the extent to which 
the effect of cladribine on 6-month CDP wanes over a 4-year 
time horizon. In the absence of long-term follow-up data, in 
previous NICE appraisals of drugs for treating MS, the wan-
ing of effectiveness over time had been assumed to be the 
same for all DMTs, namely 100% for the first 2 years, 75% 
for the next 2 years and 50% for subsequent years (Table 5).
The waning effect estimates reported in the CS were 
based on the pooled 6-month CDP data from the CLARITY 
trial and the CLARITY-EXT trial for the ITT population, 
not for the RES-RRMS and SOT-RRMS subgroups. Thus, as 
part of the clarification process, the ERG requested further 
analyses of waning using 6-month CDP and ARR for the 
RES-RRMS and SOT-RRMS subgroups.
For the RES-RRMS subgroup, the sample size was 
smaller and the number of outcomes was fewer than those 
in the ITT population, meaning that the confidence intervals 
were even wider than the confidence interval for the ITT 
population analysis of waning. For both the ITT population 
and the RES-RRMS subgroup, the confidence intervals for 
the hazard ratios used to support no waning between years 
2 and 4 were wide and included a reduction in effective-
ness of 75%. The ERG interpreted this evidence to mean 
the waning for cladribine is the same as has been assumed 
for other DMTs in previous appraisals. In their clarifica-
tion response, the company stated that, for the SOT-RRMS 
subgroup, the sample size and number of events were too 
small for the treatment-switching algorithm to generate cred-
ible results. They did, however, undertake the analysis and 
results showed that there was no evidence that the effective-
ness of cladribine waned in the SOT-RRMS subgroup.
Clinical advice to the ERG was that there is almost 
complete uncertainty around the extent, and timing, of any 
waning of treatment effect for patients with RES-RRMS or 
SOT-RRMS (or for any patients with MS) who receive any 
of the DMTs included in the company model, for the period 
beyond 2 years. The ERG considered that the evidence pro-
vided by the company was not strong enough to merit the 
application of a waning effect for cladribine that is different 
to that used for the other DMTs. Setting all treatments to 
have the same waning effect (100% up to year 2, 75% over 
years 2–4 and 50% thereafter) had no effect on the com-
pany’s base-case cost-effectiveness results, i.e. cladribine 
dominated all the comparator treatments for the RES-RRMS 
and SOT-RRMS subgroups.
3.4.3  Other Issues
The company included informal care costs and carer disutil-
ity in its base-case analyses. The ERG considered this to be 
inappropriate as these are not NHS or personal and social 
services costs. The ERG investigated the impact of exclud-
ing carer disutility and using alternative costs derived from 
previous NICE submissions.
The company’s base-case analysis assumed only a sin-
gle line of treatment. As modelling of treatment sequenc-
ing is beyond the remit of the ERG, the ERG considered it 
informative to explore time horizons significantly shorter 
than lifetime to reflect the facts that (1) patients are unlikely 
to be receiving a single treatment for life and (2) that the 
effectiveness data available for the DMTs are limited to, at 
the most, 4 years.
The company also considered that patients treated with 
cladribine and alemtuzumab could re-start with their respec-
tive medications after 4 years. Treatment re-initiation rates 
for cladribine were derived from the CLARITY-EXT trial, 
while those for alemtuzumab were derived from previous 
STAs [12, 13]. Clinical advice to the ERG was that there 
is no published evidence that re-initiation is effective. 
The ERG, therefore, considered that it was appropriate to 
remove re-exposure to cladribine and alemtuzumab from 
Table 5  Changes in drug efficacy over time that the company applied in the model. Source: Company submission, Tables 71 and 73
NICE National Institute for Health and Care Excellence
Years Cladribine Comparators
Value (%) Rationale Value (%) Rationale
0–2 100 Analysis of pooled data from 
CLARITY and CLARITY-EXT 
trials
100 Based on approaches that were accepted 
by NICE in TA441 [13]2–4 100 75
4–5 75 Based on approaches that were 
accepted by NICE in TA441 [13]
75
5+ 50 50
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the base-case analyses. The ERG also considered alternative 
treatment discontinuation rates and AE rates for all DMTs.
None of the ERG’s changes, except for shortening the 
time horizon, stopped cladribine from dominating its com-
parators. However, the cumulative impact of the ERG’s 
various amendments to the company’s base-case model did 
affect the company’s base-case conclusion for patients with 
RES-RRMS. Alemtuzumab dominated cladribine, and clad-
ribine no longer dominated daclizumab and natalizumab, 
with ICERs of £81,050 and £64,269 per QALY lost respec-
tively (Table 6).
3.5  Conclusions of the Evidence Review Group 
Report
The company presented direct clinical effectiveness evi-
dence (cladribine vs. placebo) from the CLARITY trial. 
This trial was of good quality and was well conducted. The 
RES-RRMS and SOT-RRMS subgroups and three outcomes 
(NEDA-3, time to 6-month CDP and proportion of patients 
with 6-month CDP) were defined retrospectively. The ERG 
considers that the post-hoc definitions and analyses were 
necessary to address the final scope issued by NICE, but the 
sample size for the SOT-RRMS subgroup was too small to 
detect a statistically significant difference for all outcomes. 
For the indirect evidence, the ERG noted that the results of 
the NMAs carried out by the company should be viewed 
with caution owing to the small number of studies that 
were available for the key efficacy outcomes. The ERG also 
remained unconvinced that the results of the meta-regression 
presented by the company were valid.
The effect of DMTs on slowing disability progression 
(6-month CDP) was the main cost-effectiveness driver in 
the company’s economic model. On this, for the RES-RRMS 
subgroup, the ERG and the company agreed that treatment 
cladribine was statistically significantly more effect than pla-
cebo and no more effective than treatment with other DMTs. 
However, the ERG did not agree with the company’s deci-
sion to apply a lower waning effect and discontinuation rates 
to cladribine compared to those applied to treatment with 
other DMTs. The differential rates applied were not based 
on evidence and overestimated the cost effectiveness of 
cladribine. There was no statistically significant evidence of 
effectiveness of cladribine over placebo in the SOT-RRMS 
subgroup for either 6-month CDP or qualifying ARR. There 
was therefore no basis on which to undertake an economic 
analysis. Overall, given the substantial uncertainties about 
the long-term prognosis, in terms of disability progression 
and ARR, for patients treated with DMTs, the ERG consid-
ered that any economic results produced by the company 
model, even after ERG modifications, should be treated with 
caution.
4  National Institute for Health and Care 
Excellence
The AC reviewed the evidence available on the clinical and 
cost effectiveness of cladribine alongside testimony from 
clinical experts and patient representatives.
Table 6  Cost-effectiveness results for the comparison of cladrib-
ine vs. alemtuzumab, natalizumab, daclizumab and fingolimod for 
patients with rapidly evolving severe relapsing-remitting multiple 
sclerosis (RES-RRMS) and sub-optimally treated relapsing-remitting 
multiple sclerosis (SOT-RRMS): company base-case results and 
results generated following Evidence Review Group (ERG) revisions 
to the company base case
R1 for 6-month CDP, cladribine is no more effective than placebo
For qualifying ARR, the effectiveness of alemtuzumab and daclizumab are set equal to the effectiveness of cladribine where appropriate; 
R2 = waning effect: the effectiveness of cladribine is set to 75% between years 2 and 4; R3 = no re-exposure to cladribine or alemtuzumab; 
R4 = treatment discontinuation only at EDSS state 7 after 2 years; R5 = TA32 EDSS state costs [34]; R6 = no carer disutility
ARR annualised relapse rate, CDP confirmed disability progression, ICER incremental cost-effectiveness ratio, Inc. incremental, QALY quality-
adjusted life-year
a The ICER represents the monetary gain per QALY lost rather than the cost per QALY gained
RES-RRMS Alemtuzumab Natalizumab Daclizumab
Inc. cost Inc. QALYs ICER Inc. cost Inc. QALYs ICER Inc. cost Inc. QALYs ICER
Company base case − £19,134 0.182 Dominant − £130,676 0.512 Dominant − £89,182 0.924 Dominant
ERG scenario (R1, R2–R6) £38,423 − 1.541 Dominated − £133,754 − 1.650 £81,050a − £87,566 − 1.362 £64,269a
SOT-RRMS Alemtuzumab Fingolimod Daclizumab
Inc. cost Inc. QALYs ICER Inc. cost Inc. QALYs ICER Inc. cost Inc. QALYs ICER
Company base case − £17,549 0.153 Dominant − £72,065 0.944 Dominant − £66,397 0.548 Dominant
ERG scenario (R1, R2–R6) − £8711 0.004 Dominant − 6642 0.013 Dominant − £7749 0.010 Dominant
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4.1  Clinical Need and Patient Perspective
The AC heard from a patient expert that relapses and resid-
ual disability between relapses can substantially limit a 
patient’s ability to work. The AC concluded that frequent 
hospital appointments for drug treatment and monitoring 
cause significant disruption to patients’ lives and careers. 
The AC also recognised the benefit of an oral treatment 
taken in two short courses over 2 years.
4.2  Current Practice and Comparators
The AC heard from clinical experts that many patients with 
MS do no take DMTs, but patients with highly active disease 
receive DMTs. The AC also heard from the clinical experts 
that clinicians follow NICE guidance that recommends that 
patients with RES-RRMS receive alemtuzumab or natali-
zumab. Similarly, patients with SOT-RRMS receive alemtu-
zumab or fingolimod. At the time of the AC meeting, NICE 
guidance had recommended daclizumab for patients with 
RES-RRMS and SOT-RRMS if alemtuzumab is contrain-
dicated or otherwise unsuitable. Clinical experts explained 
that patients with RES-RRMS are clinically identifiable, but 
patients with SOT-RRMS are more difficult to define. The 
AC heard from the experts that the company had defined the 
SOT-RRMS subgroup based on the number of MRI lesions. 
The clinical experts noted that it was not the number of, 
but the increase in, MRI lesions that is important for meas-
uring response to treatment. The AC, therefore, agreed to 
refer to MRI evidence of disease activity rather than use 
the company’s definition of suboptimal treatment. The AC 
concluded that the RES-RRMS and SOT-RRMS subgroups 
were representative of the population who would receive 
cladribine. The AC was satisfied that the company had cor-
rectly specified relevant comparators for the RES-RRMS and 
SOT-RRMS subgroups.
4.3  Clinical Effectiveness
The AC agreed with the ERG that evidence from the CLAR-
ITY trial showed that, compared with placebo, treatment 
with cladribine statistically significantly reduced the num-
ber of relapses experienced, and marginally, although not 
statistically significantly, delayed progression for patients 
in the RES-RRMS subgroup. The AC also considered that 
treatment with cladribine was statistically significantly more 
effective than placebo in terms of ARR, 3-month CDP and 
6-month CDP in the HDA-RRMS subgroup, a group that 
includes the RES-RRMS and SOT-RRMS subgroups. 
The AC, therefore, believed that the result in the HDA-
RRMS is generalisable to the RES-RRMS and SOT-RRMS 
subgroups.
The AC noted that, where comparative results were avail-
able from indirect analyses, the confidence intervals from 
the NMAs were wide and overlapped between all treatments 
for patients in the RES-RRMS and SOT-RRMS subgroups. 
The AC heard from the ERG that the credible intervals in 
the NMA and meta-regression overlapped for all treatments 
for patients in the RES-RRMS and SOT-RRMS subgroups. 
The AC then concluded that the effectiveness of cladrib-
ine was not statistically significantly different from the 
effectiveness of alemtuzumab, daclizumab, fingolimod or 
natalizumab in the RES-RRMS and SOT-RRMS subgroups 
based on results from the NMA and meta-regression. It also 
noted that the estimated effectiveness of cladribine, com-
pared with placebo, generated by the meta-regression for 
the RES-RRMS and SOT-RRMS subgroups was similar to 
the estimates from the NMA. The AC was concerned that 
the meta-regression analysis underestimated the efficacy of 
alemtuzumab compared with placebo. The company sug-
gested this could be explained by the differences in baseline 
risk between trials. The company then compared the effect 
sizes predicted by the meta-regression with the effect sizes 
seen in the studies that assessed alemtuzumab in the NMAs. 
The AC agreed with the ERG’s concerns that there were dif-
ferences in effect sizes that are not explained by differences 
in baseline risk, which would make the company’s approach 
invalid. The AC acknowledged the company’s attempts to 
address the data limitations but, on balance, agreed with 
the ERG that the meta-regression approach may be invalid.
4.4  Cost Effectiveness
The AC agreed that the company’s model was appropriately 
structured and that most of the assumptions were generally 
reasonable. The AC accepted most of the ERG’s amend-
ments to the company’s base-case model but noted that the 
changes did not make a substantial difference to the size of 
the company’s base-case cost effectiveness estimates. The 
ERG had argued for the exclusion of the utility decrement 
for carers, but the AC was willing to consider the impact of 
MS on carers and on carers’ HRQoL in the cost-effective-
ness analysis. The ERG updated its amendments to reflect 
the AC’s preference. The AC noted that, in isolation, none 
of the ERG’s amendments to the company model changed 
the company’s base-case results, as, for both subgroups, 
treatment with cladribine continued to dominate all other 
treatments. As a result of implementing all of the ERG’s 
amendments to the company model, treatment with cladrib-
ine remained more effective and cheaper than daclizumab, 
fingolimod or natalizumab for the relevant subgroups. Treat-
ment with cladribine was less effective and cheaper than 
alemtuzumab for both the RES-RRMS and SOT-RRMS sub-
groups, resulting in ICERs of £219,549 gained per QALY 
lost and £372,802 gained per QALY lost respectively.
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4.5  Final Guidance
The AC recommended cladribine as a treatment option for 
patients with RES-RRMS and SOT-RRMS. The final guid-
ance was published by NICE in December 2017 [3].
5  Conclusion
The main issues ecountered during this STA stermed from 
the post-hoc definition of subsubgroups and clinical out-
comes. The evidence provided by the company focused on 
the use of cladribine for patients with RES-RRMS and SOT-
RRMS. The company had expected a marketing authorisa-
tion from the EMA for the use of cladribine in patients with 
HDA-RRMS, for which RES-RRMS and SOT-RRMS are 
subgroups, yet the company did not provide any economic 
evidence for patients with HDA-RRMS.
The effect of DMTs on slowing disability progression 
was the largest driver of cost effectiveness in the economic 
model. Sample sizes for the RES-RRMS and SOT-RRMS 
subgroups were small, thus there was insufficient direct 
clinical effectiveness evidence for the ERG to conclude 
that cladribine was better than placebo in reducing disease 
progression. The indirect evidence was also weak for the 
subgroups. However, both the direct and indirect evidence 
showed that treatment with cladribine was statistically sig-
nificantly better than placebo in delaying disease progression 
and in reducing the relapse rate. The AC made the decision 
to recommend the use of cladribine for patients with RES-
RRMS and SOT-RRMS based on the clinical effectiveness 
result in the HDA-RRMS population, for which an economic 
evidence should have been provided.
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